Drug intelligence / Profile preview

saline placebo-University of Saskatchewan-COVID-19

Development stage: Unknown
Lead developer: University of Saskatchewan
Modality: Small Molecules
Administration: Intramuscular

Overview

This is a saline placebo control used in clinical trials conducted by the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO). Specifically, it was utilized in the Phase 1 COVAC-005 clinical trial to evaluate the safety and immunogenicity of the COVAC-1 protein subunit COVID-19 booster vaccine in healthy adults. The placebo consists of a sterile saline solution (salt water) without any active pharmaceutical ingredients, antigens, or adjuvants. It is administered via intramuscular injection to a control group to provide a baseline for comparison against the investigational COVAC-1 vaccine's safety profile and immune response.

Other names: Saline Placebosaline solution

Beyond the preview

Go deeper on saline placebo-University of Saskatchewan-COVID-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on saline placebo-University of Saskatchewan-COVID-19.